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ABSTRACT 
Topical therapy is commonly used for the treatment of nail diseases such as onychomycosis and 
nail psoriasis due to less severe side effects, non-invasiveness, direct drug delivery at the site of 
infection, patient compliance and lower cost of treatment. However, topical treatment is limited 
due to poor permeability and hard nature of nail plate.  
     The main objective of first project was to investigate the penetrability of apremilast into and 
across the nail plate, followed by the preparation of a novel nail lacquer formulation to improve 
its ungual and trans-ungual permeation for the treatment of nail psoriasis. Dexpanthenol and 
salicylic acid were found to be the potential permeation enhancers. The final nail lacquer 
formulation showed the ability to form a water resistant film on nail plate and delivered 
significant amount of apremilast into the nail apparatus.           
     In second project, iontophoresis technique was investigated to improve the ungual and trans-
ungual permeation of itraconazole for the treatment of onychomycosis. In vitro and ex vivo 
permeation studies were performed following two protocols, a) pulse application of 
iontophoresis for 3 days (8 h/day), b) continuous application of iontophoresis for 24 h. The 
results of in vitro and ex vivo studies demonstrated the feasibility of iontophoresis technique to 
enhance nail delivery of itraconazole. Pulsed application of iontophoresis was found to be 
superior over continuous application of iontophoresis in all cases. 
      In third project, a novel hyponychium pathway was investigated to deliver drugs directly into 
the ventral layer of nail plate and other part of nail apparatus using iontophoresis as an active
iii 
 
technique. In vitro and ex vivo studies resulted that hyponychium pathway can be a viable option 
to deliver significant amount of drug into nail apparatus by the application of iontophoresis 
technique.  
     In final project, pre-treatment with solid microneedle was investigated to improve the 
availability of drugs in nail apparatus. The application of microneedles has not been explored 
before to improve nail delivery of drugs. Microneedle pre-treatment is a novel approach which 
has already been used to deliver small and large molecules into the skin in a minimally invasive 
manner.  
 
 
.  
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CHAPTER 1: INTRODUCTION 
Onychomycosis is a fungal infection in the toe and finger nails that is mainly caused by 
Trichophyton rubrum and candida (dermatophytes).1 The fungus mainly invades and colonizes in 
nail plate, nail bed and matrix. It commonly starts from the hyponychium and distal or lateral 
nail bed and then spread all over the nail apparatus.2 Approximately, 2-13% of general 
population is affected by onychomycosis.3 People who suffer from conditions such as diabetes, 
peripheral vascular diseases and immunodeficiency disorders have been reported to have more 
vulnerability to onychomycosis. It also affects patient’s emotional, social and occupational life.3 
      Nail psoriasis is a chronic inflammatory disease. It occurs approximately 50% of the skin 
psoriatic patients.4 The common symptoms of psoriatic nail are pitting, onycholysis, 
discoloration, subungual hyperkeratosis, splinter hemorrhages. Although the theory behind the 
nail psoriasis occurrence is still not clear, its development is speculated due to the combination 
of genetic, immunologic and environmental factors.5-7 
      The treatment of nail diseases via systemic administration of drugs is not completely 
successful due to poor blood circulation into the nail apparatus.3,8-10 Topical treatment is a 
emerging therapy which is considered to be most effective way of treatment of nail disease due 
to non-invasiveness, targeted drug delivery, fewer side effects, cost effectiveness and patient 
compliance.3 However, poor permeability of nail plate limits the topical delivery of drugs.2,3 Nail 
plate is known to possess three layers which are dorsal, intermediate and ventral.1,2 Ventral layer 
is directly attached to the nail bed and relatively more hydrated than other two layers. According 
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to the previous literature, dorsal layer is considered as the main barrier for drug permeation due 
to its thickly packed structure with keratin and cells.11 
     In the following project, several active (Iontophoresis, solid microneedles) and passive [nail 
permeability enhancers (NPEs)] techniques were used to enhance the ungual and trans-ungual 
delivery of drugs.12 The application of nail permeation enhancers is the most widely used 
approach which works by several mechanisms. Some permeation enhancers break the disulfide 
bonds in the nail plate and some enhance the water holding capacity of nail plate.12 
 
Figure 1. Anatomy of nail apparatus 
     Iontophoresis is one of the widely studied active technique that enhances the permeation of 
drugs by the way of passing electrical current across nail plate.
12-16
 The amount of drug delivered 
is directly proportional to the amount of current applied, duration of current application and area 
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of the nail surface in contact with active electrode. The amount of delivery of drugs can be 
regulated by adjusting the applied electrical dose (time x current density).
12-16
 
     Microneedle pre-treatment is novel approach which has already been used to deliver small 
and large molecules into the skin in a minimally invasive manner.
17-19
 The application of 
microneedles has not been explored before to improve nail delivery of drugs.
18,53
 In this project, 
solid microneedle pre-treatment was investigated as an approach to enhance the delivery of drugs 
into the nail apparatus. 
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CHAPTER 2: A NOVEL NAIL LACQUER FORMULATION FOR TRANS-UNGUAL 
DELIVERY OF APREMILAST 
1.0 Introduction 
Apremilast is recently approved by FDA as solid oral dosage form for the treatment of skin and 
nail psoriasis.
5-7
 According to clinical studies, an approximately 33.3 % of nail psoriasis patients 
showed 50% reduction in nail psoriasis severity index (NPSI) when they were administered 
apremilast tablets twice a day for 16 weeks. However, in case of placebo, 14.9% of patients 
showed 50% reduction in NPSI.
20
 Oral administration of apremilast is associated with severe 
side effects such as diarrhea, headache, nausea, upper respiratory tract infection, vomiting, runny 
or stuffy nose or abdominal pain.
20,21 
           The current project was designed to investigate the penetrability of apremilast into and 
across the nail plate, followed by the preparation of a novel nail lacquer formulation to improve 
its ungual and trans-ungual permeation.  
2.0 Materials and methods 
Apremilast was purchased from Medkoo Biosciences (Chapel hill, NC). All the surfactants and 
humectants were gifted by BASF (West Memphis, AR). Cadaver human nails were purchased 
from Science care (Phoenix, AZ). The solvents were purchased from Fisher Chemicals (Hanover 
Park, IL). Eudragit® S 100 [Methacrylic Acid - Methyl Methacrylate Copolymer (1:2)] was 
gifted by Evonik Industries (Germany).  
2.1. Preparation of nail lacquer formulation 
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Nail lacquer formulation was prepared using Eudragit
®
 S 100 (8% w/w) as a film forming 
polymer.  The mixture of ethanol, ethyl acetate and water (63:30:7) were used as a solvent 
system. In first step, Eudragit
®
 S 100 and apremilast (1 mg/ml) were completely dissolved in 
ethanol, ethyl acetate and water mixture by continuous shaking on tube rotator for 2 h. Finally, 
an enhancer was accurately weighed according to table 1 and added to nail lacquer formulation. 
The enhancers were screened individually by incorporating in nail lacquer formulation.  
 
 
 
 
 
 
 
 
Table 1. The list of excipients screened for potential permeation enhancement of apremilast.  
2.2. Screening of novel permeation enhancers 
Human nail plates (0.07cm
2
) were used to perform screening studies. Permeation enhancers were 
screened using TranScreen-N high throughput technique which was mentioned by Nair, et al. 
Prior to start an experiment, all nail plates were soaked in phosphate buffer saline (PBS) for 
atleast 2 h. Each nail plate was treated with 100 µl of nail lacquer formulation at room 
temperature for 24 h. Upon the treatment period, nail plates were washed five times with ethanol 
and then pat dried with Kimwipes
®
. Each nail plate was weighed precisely and solubilized in 2 
ml of 1 M sodium hydroxide solution by shaking overnight on tube rotator. Hydrochloric acid 
Name of the enhancer % w/w 
 Vitamin E TPGS 5 
Salicylic acid 5 
Dexpanthenol 10 
Tocopherol 2 
Polyethylene glycol 400 10 
Kolliphor
TM
 RH 40 10 
Kolliphor® EL 10 
Kolliphor
TM
 HS 15 5 
Kolliphor® CS 20 5 
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(0.4 ml, 5 M) was used to neutralize the alkaline solution, followed by adding 2 ml of ethyl 
acetate as an extraction solvent. The final mixture was centrifuged at 3000 g for 10 min to 
separate the solvent layers. Ethyl acetate layer was collected and evaporated using nitrogen gas 
evaporator to recover the solid crystals of apremilast. Finally, the amount of apremilast was 
reconstituted in 1 ml of ethanol and quantified using HPLC.
22 
2.3. Characterization of nail lacquer formulation 
2.3.1. Stability studies 
Stability studies were performed following ICH guidelines recommended for zone II 
(Mediterranean and subtropical) at 25 ̊C ± 2 ºC temperature and 60% ± 5% RH (relative 
humidity) for 3 months.
23
 During stability studies, samples of nail lacquer formulation were 
collected every month. The amount of apremilast contained in the samples was quantified using 
HPLC method.   
2.3.2. Drying time 
Approximately 20 µl nail lacquer formulation was applied on human cadaver nail plate and 
recorded the duration to form a complete dry film.
24
 
2.3.3. Differential scanning calorimetry (DSC) 
DSC (PerkinElmer, California) was used to investigate the solid state nature of apremilast 
existed in a film formed by nail lacquer formulation. DSC thermogram was recorded for 
apremilast, the film formed by nail lacquer formulation and other excipients at heating rate of 30 
0C/min in the range of 30 0C to 200 0C. The flow of nitrogen gas was maintained at 22 ml/min.3 
2.3.4. Fourier Transform Infrared Spectroscopy (FTIR) 
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FTIR spectroscopy (Cary 660, Agilent Technologies Santa Clara, CA) was performed to evaluate 
the interactions between excipients and apremilast. FTIR spectra were recorded in the range of 
700 - 4000 nm wavelength.   
2.3.5. Bioadhesivity of nail lacquer formulation 
Bioadhesivity could significantly influence the performance of nail lacquer formulation. Texture 
Analyzer equipped with a 50-kg load cell (TA XT2i, Technologies Corp, Scarsdale, NY/ Stable 
Micro Systems, Godalming, Surrey, UK) was used to measure the bioadhesive property. Nail 
lacquer formulation was applied on a glass slide that was placed on bottom surface of the 
instrument. Approximately, 0.64 cm
2
 human cadaver nail plate was attached with TA-10 probe 
and dropped it from height of 25 mm at a speed of 1 mm/s with a force of 3.5 N till nail plate 
touched to the nail lacquer formulation. Nail plate was kept in contact with nail lacquer 
formulation for 30, 60, or 120 s. The peak force and work of adhesion applied to detach nail 
plate from nail lacquer formulation were measured and then the results were interpreted using 
Texture Expert
TM
 software.
24
 
2.3.6. Loss on washing studies 
The washing studies were performed on human cadaver nail to assess the water resistance 
property of a film formed by nail lacquer formulation. Prior to start an experiment, all the nails 
were cleaned with 70% alcohol and pat dried with Kimwipes
®
. Then, 20 µl of nail lacquer 
formulation was applied gently on each nail. After complete drying of film, each nail was 
washed 10 times separately with 1 ml of distilled water. The amount of apremilast contained in 
washing samples was quantified using HPLC.
24
 
2.4 In vitro transport studies   
Transport studies were performed across human cadaver nail plate using Franz diffusion cells for 
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7 days. Before starting an experiment, nail plates were soaked in phosphate buffer saline (PBS) 
for 2 h. Then, they were washed with distilled water and pat dried with Kimwipes
®
. Each nail 
plate was secured between donor and receiver compartments with an adapter having 0.3 cm
2
 
active diffusion area. The top compartment was filled with 100 µl of nail lacquer formulation. 
The bottom compartment was filled with 20% ethanol. Control was used as a nail lacquer 
formulation without permeation enhancers. The solution in the bottom compartment was stirred 
continuously during transport studies using 3 mm size magnetic bar at 600 rpm. Samples were 
collected from the bottom compartment at certain period of time. The amount of apremilast 
found in the samples was quantified using HPLC.
13-16
 
2.5 Extraction of apremilast from nail plate    
After transport studies, an active diffusion area of the nail plate was excised using 0.3 cm
2
 metric 
punch. The nail plates were washed 5 times properly with 70% of ethanol and wiped off with 
Kimwipes
®
. Each nail plate was accurately weighed and solubilized in 2 ml of 1 M sodium 
hydroxide solution by shaking overnight. Hydrochloric acid (5 M, 400 µl) was added to 
neutralize sodium hydroxide solution. Then, 2 ml ethyl acetate was added to extract apremilast 
from the suspension. The final mixture was centrifuged at 3000 g for 10 min. Ethyl acetate layer 
was collected and evaporated using nitrogen gas evaporator to recover the solid crystals of 
apremilast. Finally, the amount of apremilast extracted from the nail plate was reconstituted in 
ethanol and quantified using HPLC. The amount of apremilast diffused in peripheral area of the 
nail plate was extracted following same process which was used for extraction of apremilast 
from active diffusion area.
13-16
 
2.6 Human subject studies            
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Human ethical committee of Visveswarapura Institute of Pharmaceutical Sciences, Bangalore, 
India approved the protocol and study design. Six healthy human volunteers in the age range of 
25-35 year old participated in human subject studies. The volunteers were divided into two 
groups: group I was treated with control formulation (nail lacquer formulation without 
enhancers) and group II was treated with nail lacquer formulation. Prior to application of the 
formulations, volunteers were asked to clean the finger and thumb nails with 70% alcohol and 
pat dried with Kimwipes
®
. Approximately, 20 µl of nail lacquer formulation was applied on each 
nail plate twice in a day for 15 days. All the volunteers were instructed to avoid cleaning their 
hands before complete drying of nail lacquer formulation. After 15 days of treatment, distal edge 
of nail plate was excised and weighed respectively. The amount of apremilast retained in nail 
plate was extracted using solvent extraction method. Ethyl acetate was used as an extraction 
solvent. Section 2.5 describes the complete extraction procedure.
24
 
2.7. Analytical method 
The amount of apremilast was quantified using high performance liquid chromatography system 
(HPLC, waters, 1525) comprising of an auto sampler (waters 717 plus), Cogent Bidentate C18 
analytical column (4.6 mm × 150 mm, Luna, 5.0 µm), waters dual wavelength UV detector 
(2487). Isocratic HPLC method was performed at 32 0C using a flow rate of 1.0 ml/min. 
Apremilast was eluted at 254 nm with mobile phase consisting of acetonitrile and nanopure 
water (60:40). The pH of the mobile phase was adjusted with 0.1 % of orthophosphoric acid. The 
HPLC method was validated from the range of 0.01 to 10 µg/ml (R2 = 0.99).25 
2.8. Statistical analysis 
One-way ANOVA test was performed for statistical analysis of data using SPSS software. The 
data was considered to be statistical significant as p value found less than 0.05.   
10 
 
3.0 Results and Discussion 
Topical therapy is a new emerging therapy for the treatment of nail psoriasis. In recent years, 
permeation enhancers have been widely used to improve the permeation of drugs across the nail 
plate. Some enhancers work as a moisturizer (enhance the water holding capacity of the nail 
plate) and some break the disulfide bonds of keratin in nail plate.
12
 In current project, several 
surfactants, humectants and keratolytic agents were screened to improve the permeation of 
apremilast into and across the nail plate (Table 1). Eudragit
®
 S 100 was used as a film forming 
polymer to improve the adhesivity of nail lacquer formulation with nail plate for long period of 
time. Propylene glycol 400 was used as a moisturizing agent.  
             High throughput TranScreen-N method was used to screen nail permeation enhancers. 
As a result of screening studies, dexpanthenol and salicylic acid were found to be the most 
potential enhancers which were used as the moisturizing and keratolytic agents.
26,27
 The result of 
screening studies is presented as the amount of apremilast retained in nail plate per total weight 
of nail plate. The amount of apremilast retained in nail plate after application of formulations 
containing dexpanthenol and salicylic acid was ~2 (13.5±1.2 µg/mg) and ~3 (16.8±2.6 µg/mg) 
fold more relative to control (5.7±0.9 µg/mg) [p<0.05]. Figure 2 illustrates the screening studies 
data. 
11 
 
 
Figure 2. The result of TranScreen-N for identifying the potential enhancers. The data represent 
mean ± SD of six determinations. *[p<0.05], ** [p<0.05] 
Number Excipients % w/w 
1 Apremilast 0.1 
2 Salicylic acid 5 
3 Dexpanthenol 10 
4 PEG 400 5 
5 Eudragit® S 100 8 
6 Water 5 
7 Alcohol 45.3 
8 Ethyl acetate 21.6 
 
Table 2. The composition of apremilast nail lacquer formulation 
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            Stability studies resulted that nail lacquer formulation was able to stabilize ~ 97.8% of 
apremilast over 3-month period of time at 25 ̊C/60% RH (Table 3). Drying time studies revealed 
that nail lacquer formulation was able to form a dry film on human nail plate in ~55 sec.  
 % stability of apremilast in the nail lacquer formulation at 25 ̊C/60% RH 
Time 0 month 1 month 2 months 3 months 
 100.1±1.15 98.5±1.59 97.08±0.6 97.8±1.02 
 
Table 3. The results of stability studies of apremilast nail lacquer formulation. The data represent 
mean ± SD of three determinations. 
             DSC was performed to investigate the solid state nature of apremilast in nail lacquer 
film. According to DSC thermogram, the pure API of apremilast showed the endothermic peak at 
163.8 ºC (Figure 3). However, in case of nail lacquer film, the endothermic peak was absent 
which indicates the conversion of apremilast into amorphous form or in solid-solid solution.   
 
Figure 3.DSC thermogram of apremilast nail lacquer formulation, excipients and physical 
mixture of apremilast with excipients. 
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           FTIR analysis was performed to investigate the formation of new hydrogen bonds 
between apremilast and Eudragit
®
 S 100 polymer in nail lacquer film. FTIR spectra were 
recorded for the apremilast, Eudragit® S100 and a nail lacquer film with permeation enhancers. . 
As a presence of permeation enhancers may affect the proper understanding of drug-polymer 
interaction, the nail lacquer film was prepared devoid of penetration enhancers.  
The structure of apremilast illustrates that it can potentially act as either proton acceptor 
(amide and ketone carbonyl groups, -C=O) or proton donor (amide functional group, -NH-
COCH3) (figure 3). The stretching vibration of amide –C=O, ketone –C=O, and amide –N-H 
groups of apremilast was found at 1687 cm
-1
, 1763 cm
-1 
and 3362 cm
-1 
(figure 4). The structure 
of Eudragit
®
 S 100 polymer has one proton acceptor (carbonyl, C=O) and one proton donor 
(hydroxyl, -OH) which showed the stretching vibration at 1724 cm
-1 
(carbonyl group) and 3445 
cm
-1
 (hydroxyl group) (figure 4). 
       FTIR spectra of nail lacquer illustrated the shift in the stretching vibration of carbonyl and 
amide –N-H groups of apremilast which were recorded at 1699 cm-1, 1781 cm-1 and 3399 cm-1. 
According to previous literature, the shift in the stretching vibrations indicates the formation of 
new hydrogen bonds between drug and polymer. In the case of nail lacquer, the peaks at 1699 
cm
-1 
and 1781 cm
-1 
were attributed to apremilast carbonyl groups which formed H-bonds with 
the polymer, whereas a new peak at 3399 cm
-1 
was characterized to apremilast amide –N-H 
group that formed H-bond with the hydroxyl group of the polymer (Figure 4). 
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Figure 4. FTIR Spectra of apremilast nail lacquer formulation and excipients.  
            The Peak force and work of adhesion were found to increase with enhancement of 
contact time between the nail plate and nail lacquer formulations (placebo and apremilast load) 
(Figure 5, 6). The peak force and work of adhesion at any contact time period were higher for the 
placebo lacquer compared to apremilast-loaded lacquer, while there was no significant difference 
found between each other (p > 0.05). To conclude, apremilast-loaded nail lacquer film was found 
to have sufficient adhesiveness to be retained on the surface of nail plate for prolonged period of 
time. In addition, its adhesivity was not changed significantly after adding drug and other 
excipients compared to placebo.   
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Figure 5. Peak adhesive force (N) of apremilast loaded nail lacquer formulation and placebo. 
The data represent mean ± SD of three determinations. (p>0.05) 
 
Figure 6. Adhesion of apremilast loaded nail lacquer formulation and placebo. The data 
represent mean ± SD of three determinations. (p>0.05) 
            Loss on washing (LOW) studies was performed on human cadaver nails. The amount of 
apremilast lost after 10
th
 washing was approximately ~5% of the total amount contained in nail 
lacquer formulation (Figure 7). 
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Figure 7.  The cumulative amount of apremilast lost after 10 times washing a film formed due to 
application of nail lacquer formulation. The data represent mean ± SD of three determinations. 
            After 7 days of In vitro permeation studies, the amount of apremilast found in the 
receiver compartment in case of nail lacquer formulation was 0.52±0.07 µg/cm
2
 which was ~3 
fold more when compared with control (0.19±0.02 µg/cm
2
) (Figure 8). The amount of apremilast 
retained in the nail plate after transport studies in case of nail lacquer formulation (1.26±0.18 
µg/mg) was ~2 fold more compared to control (0.57±0.07µg/mg) (Figure 9).  The amount of 
apremilast diffused in the peripheral area was 0.39±0.09 µg/mg which was ~2 fold more 
compared to control (0.23±0.06 µg/mg) (Figure 10). According to a result of in vitro studies, nail 
lacquer formulation was able to deliver significant amount of apremilast into and across the nail 
plate related to control (p<0.05). 
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Figure 8: The amount of apremilast permeated across the nail plate after 7 days of in vitro 
permeation studies. Control was used as a nail lacquer without permeation enhancers. The data 
represent mean ± SD of six determinations. 
 
Figure 9: The amount of apremilast retained in active diffusion area of the nail plate after 7 days 
in vitro of permeation studies. Control was used as a nail lacquer without permeation enhancers. 
The data represent mean ± SD of six determinations. 
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Figure 10: The amount of apremilast retained in the peripheral area of the nail plate after 7 days 
of in vitro permeation studies. Control was used as a nail lacquer without permeation enhancers. 
The data represent mean ± SD of six determinations. 
              Human subject studies were performed to verify the results of in vitro studies. Six 
human volunteers participated in the studies who were in the age range of 25-35 year old. The 
amount of apremilast retained in nail plate after 15 days application of nail lacquer formulation 
was 0.93±0.14 µg/mg, whereas it was 0.41±0.04 µg/mg in case of control. Clinical studies 
concluded that nail lacquer formulation was able to improve the loading of apremilast in nail 
plate ~2 fold more compared to control.   
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Figure 11: The amount of apremilast retained in nail plate of human volunteers. The volunteers 
were divided in two groups, each group had 3 volunteers. Nail lacquer formulation was applied 
on two nails of each hand (thumb and index finger) of group I volunteers. Control (nail lacquer 
without enhancers) was applied on two nails of each hand (thumb and index finger) of group II 
volunteers. 
4.0 Conclusions 
 Nail lacquer formulation showed the ability to form a water resistant film on the nail plate which 
retained the drug on nail plate for prolonged duration and facilitated drug penetration into the 
nail plate. Permeation enhancers were able to render the formulation relatively more efficient in 
enhancing the amount of apremilast delivered into and across the nail plate from the topical nail 
lacquer formulation. 
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CHAPTER 3: TRANS-UNGUAL DELIVERY OF ITRACONAZOLE 
HYDROCHLORIDE BY IONTOPHORESIS 
1. Introduction  
Itraconazole (ITR) is a triazole antifungal drug for the treatment of onychomycosis.12 However, 
long time oral use of ITR is known to cause severe gastric and systemic side effects such as 
nausea and vomiting.3 According to the FDA, “patients who have signs of ventricular 
dysfunction such as congestive heart failure or a history of congestive heart failure should not 
take ITR orally for treatment of onychomycosis”.33 
            Passive trans-ungual delivery of drugs is limited due to hard nature of the nail plate.1 In 
current project, iontophoresis technique was used to deliver ITR across the nail plate. ITR-HCl 
salt was prepared to render it amenable to iontophoresis. In previous literatures, iontophoresis 
has been reported as a successful technique to deliver the significant of drug into the nail 
apparatus.13-16,30 
2. Methods and materials 
2.1 Materials 
Itraconazole (ITR, molecular weight = 705.2) was purchased from VWR International (Atlanta, 
GA). Phosphate buffer saline at pH 7.4 (0.138 M of sodium chloride, 0.0027 M potassium 
chloride) and acetonitrile were purchased from Omnipur and Fisher Chemicals (Hanover Park, 
IL). Excised human cadaver toes were purchased from Science Care (Phoenix, AZ). The Porcine 
hoof was obtained from Pontotoc slaughtering house (Mississippi, USA). 
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2.2 Synthesis of ITR-HCl 
ITR suspension (40 g/800 mL of acetone) was prepared in a round bottom flask with three necks. 
Anhydrous hydrogen chloride gas was bubbled slowly into the suspension while heated under 
reflux. Hydrogen chloride gas was prepared using solid sodium chloride and concentrated 
sulfuric acid (H2SO4). After 30 min continuous heating, the suspension turned into solution and 
eventually in the next 5-10 min, ITR-HCl was precipitated. The hydrogen chloride gas was 
continued to pass for next 2 h. The slurry was allowed to stand for 24 h and then the precipitate 
was collected, washed with acetone and dried at 400 C.34 
2.3 Characterization of ITR-HCl  
2.3.1 Differential scanning calorimetry (DSC) 
The DSC (PerkinElmer, California) for ITR and ITR-HCl was recorded in the range of 30 0C to 
250 0Cat a heating rate 10 0C /min and nitrogen flow rate of 22 ml/min.  
2.3.2 Mass spectroscopy  
Mass spectroscopy of ITR and ITR-HCl was performed using matrix-assisted laser 
desorption/ionization technique (MALDI- SYNAPT MS/HDMS). Dimethyl sulfoxide was used 
to dissolve the samples. Samples were scanned from intensity of 200 m/z to 5000 m/z.  
2.4 Solubility measurement 
Solubility studies of ITR-HCl was carried out in water, isopropanol and mixtures of water and 
isopropanol (90:10, 80:20, 70:30, 60:40 and 50:50 v/v percentage) at pH 3 for preparing 
appropriate solution to perform iontophoresis. The pH of the solvent system was adjusted using 
0.01 N HCl. Excess amount of ITR-HCl was added to the solvents and sonicated for 15 min at 
room temperature. Suspensions were shaken continuously on the rotary shaker for 2 days, and 
then filtered using disposable syringe filters (0.45 µm). Amount of dissolved ITR was estimated 
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by HPLC. 
2.5 Antifungal activity testing of ITR and ITR-HCl 
Clinical and laboratory standards institute method was used for antifungal activity testing of ITR 
and ITR-HCl. Testing Organisms were obtained from the American Type Culture Collection 
(Manassas, VA) (Candida albicans, Candida krusei, Cryptococcus neoformans, Aspergillus 
fumigatus, Trichophyton Rubrum). The suspensions of testing organisms for Candida and 
Cryptococcus species were prepared from 3-5 colonies using sabouraud dextrose (SD) agar in 
sterile normal saline and incubated for 24 -72 h. In the case of trichophyton species, potato 
dextrose medium was used to prepare the suspension and allowed to incubate for 1 to 2 weeks. 
Standard curves between optical density and CFU/ml of saline suspensions of test organisms 
were prepared to calculate the sample assay inocula at 630 nm. 
               Assay inocula were prepared by diluting organism suspension in the incubation broth 
(RPMI 1640 broth for Candida spp., SD broth for C. neoformans, and 5% Alamar blue–RPMI 
1640 broth for Trichophyton spp) to reach the final inocula (1.5 ×10
3
 CFU/ml for Candida spp. 
and Cryptococcus spp. or 2.7×10
4
 CFU/ml for Trichophyton spp). Verification of inocula for 
each assay was carried out by platting on SD or PD agar for colony reckoning.  
             ITR and ITR-HCl samples were diluted by 20% dimethyl sulfoxide-saline to provide 
enough volume for all organisms and transferred in duplicate to 96 well flat-bottom microplates. 
ITR and ITR-HCl samples were assayed using two folds serial dilutions by preparing a total of 
11 test concentrations. 10 µL of all diluted samples were transferred in duplicate microplate as in 
template and made up the final volume up to 200 µl of all diluted samples using organism 
inocula.
35
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           Reading of Candida spp. and C. neoformans in the duplicate microplates were done using 
the Biotek Power wave XS plate reader at 530 nm after and before incubation (Candida spp. at 
35 °C for 48 h; C. neoformans at 35 °C for 72 h). Reading of A. fumigatus and Trichophyton spp 
were carried out using the Polarstar Galaxy plate reader (BMG Lab Technologies, Germany) at 
the excitation and emission wavelength of 544 nm and 590 nm prior to and after incubation 
(Trichophyton spp. at 35 °C for 5 days). IC50, MIC and MFC were calculated using the XLFit 
software (dose-response model 201; IDBS, Alameda, CA).
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The Minimum inhibitory concentration (MIC) is defined as the lowest concentration that allows 
no detectable growth (or no more than 20% growth for the azoles and caspofungin). The 
Minimum fungicidal concentration (MFC) is defined as the lowest test concentration that allows 
no growth of the organism on agar. Half-maximal inhibitory concentration (IC50) is defined as a 
quantitative measurement of amount of drug that is needed to inhibit half of the biological 
process.
35 
2.6 In vitro drug transport studies across hoof membrane 
In vitro drug transport studies were performed across the porcine hoof membrane as a model for 
human nail using Franz diffusion cells. Hoof membrane was excised, cleaned and prepared to 
have a thickness of 150-200 µm using scalpel. The hoof membrane was hydrated with phosphate 
buffer saline overnight prior to securing it between donor and receiver compartments. Active 
diffusion area (0.3 cm2) of the hoof membrane used to perform transport studies. For 
iontophoresis, platinum and silver chloride electrodes were fixed at 2 mm distance from the hoof 
membrane in the donor and receiver compartments respectively. Constant DC current (0.5 
mA/cm2) was applied using custom designed iontophoresis device (Active dose II iontophoresis 
delivery unit, Transport Pharmaceuticals, Boston, MA). The donor compartment was filled with 
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0.5 ml of ITR-HCl solution prepared by dissolving 1 mg of drug in 1 mL of water and 
isopropanol (1:1) mixture at pH 3. Receiver compartment was filled with 5 ml mixture of 
isopropanol and phosphate buffer saline (1:1) mixture at pH 3. 3 mm magnetic bars were used to 
stir (600 rpm) the solution in receiver compartment for uniform distribution of the drug. Passive 
transport studies were performed simultaneously using same set up of Franz diffusion cells 
without application of current. Samples (200 µl) were collected at fixed time points from the 
receiver compartment and analyzed by HPLC.3,16 
The passive and iontophoresis transport studies were performed following two different 
protocols. First protocol included continuous studies for 24 h and Pulsed protocol involved 
transport studies for 8 h/day for three days. In case of continuous protocol studies, the 
formulation in the donor was replaced every 8 hours with fresh formulation.  In the pulsed mode, 
the hoof surface was washed after each 8-hour episode of transport studies and allowed to be in 
contact with the receiver compartment for remaining 16 hours.   
2.7 Extraction of ITR from hoof membrane  
After in vitro transport studies, the hoof membrane was detached from the adapter. Active 
diffusion area (0.3 cm2) of the membrane was marked and excised using metric punch apparatus 
before washing. Each nail plate was washed out by shaking (2 times) in the water and 
isopropanol mixture (1:1 at pH 3) and 95% ethanol with the help of forceps. This process was 
performed alternatively five times with both solvents. The nail plate was wiped each time using 
Kimwipe®. Each plate was cut into small pieces and solubilized in 2 ml of 1 M sodium 
hydroxide solution by subjecting to ultrasonic treatment at 37 0C for 2 h.  6 ml of ethyl acetate 
was added to the final solution and ethyl acetate layer was separated out to another glass vial. 2 
ml of 1 M hydrochloric acid was added to the remaining sodium hydroxide layer for reverse 
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extraction. To this solution, another 6 ml of ethyl acetate was added and ethyl acetate layer was 
separated out to another glass vial. Both ethyl acetate glass vials were mixed together and ethyl 
acetate was evaporated using nitrogen gas to get solid crystals of ITR-HCl. Finally, ITR-HCl was 
dissolved in water and isopropanol mixture (1:1) at pH 3 prior to analysis.36 
2.8 Iontophoresis with excised human cadaver toe 
Hydroxypropylmethyl cellulose gel (2% HPMC) incorporated with ITR-HCl was prepared using 
water and isopropanol (1:1) mixture adjusted to pH 3. Excised human cadaver toe model was 
used to perform the ex vivo drug transport studies. The cadaver toes were dipped in 0.5 % 
gentamycin solution and dried one day prior to use in the study and stored at -20 °C, the toes 
were thawed at room temperature and then the studies were performed at room temperature 
conditions. Custom-designed patch was prepared to carry out the transport studies similar to that 
discussed earlier16. Adhesive backing membrane was used to fix electrode to the nail plate. 
Polyurethane foam pad was used to expose the drug and current on the fixed area. HPMC gel 
was filled up in the fixed area using spatula. Counter electrode filled with conductive gel (no 
drug) was adhered to the bottom of the toe. Anodal and cathodal electrodes were used as the 
active and counter electrodes respectively. A constant DC (0.5 mA/cm2) was applied for 24 h 
(again following two different protocols as described in section 2.6) using iontophoresis device. 
Passive transport studies were performed simultaneously with iontophoresis studies using same 
set up on the toe without current application. The amount of drug was estimated by HPLC after 
extraction of drug from the nail plate and nail bed.16,37 
2.9 Extraction of ITR from nail plate and nail bed 
Following transport studies, the nail plate was detached from the intact toe using blunt forceps 
and scalpel. Nail surface was washed (protocol discussed in section 2.7) to get rid of the adhering 
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drug. Active diffusion area of nail plate was excised using a metric punch. Eventually, amount of 
ITR was extracted from the nail plate and measured. 
             Nail bed was separated carefully from the intact toe. Nail bed was homogenized and 
dissolved in the 1 M sodium hydroxide. The drug was extracted from sodium hydroxide solution 
using same procedure, detailed in section 2.7.36 
2.10 Analytical method 
The amount of ITR was determined by high performance liquid chromatography system (HPLC, 
waters, 1525) consisting of an auto sampler (waters 717 plus), phenomenex C18 (2) 100 R 
analytical column (4.6 mm × 150 mm, luna, 5.0 µm), waters dual wavelength UV detector 
(2487). Mobile phase was prepared by combination of three solvents, Acetonitrile, nanopure 
water and diethylamine (70:30:0.05). Elution of drug was carried out isocratically at 32 0C using 
a flow rate of 1.0 ml/min and 30 µl injection volume. ITR was detected at 261 nm. Calibration 
curve was prepared using a range from 0.01- 10 µg/ml (R2 = 0.99).33 
2.11 Statistical analysis  
Statistical analysis of ITR-HCl permeation studies was performed by student t-test using SPSS 
software. The P value less than 0.05 was considered significant difference.    
3. Results and Discussion  
ITR-HCl was characterized by Differential scanning calorimetry (DSC) and MASS spectroscopy. 
According to the DSC thermogram, sharp melting endothermic peak was found in case of ITR at 
171 0C (Figure 17). However, endothermic melting peak was not found in case of ITR-HCl 
indicating likely modification of the base into salt.33 
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Figure 12. DSC (PerkinElmer, California) thermogram of ITR and ITR –HCl 
           Mass Spectroscopy of ITR and ITR-HCl was carried out by Matrix-assisted laser 
desorption/ionization technique (MALDI- SYNAPT MS/HDMS). According to mass spectra, 
peak of ITR was found at 705.64 m/z. ITR-HCl formation was confirmed by appearance of peak 
at ~ 741.02 m/z.  
                 Solubility studies of ITR-HCl were performed in water, isopropanol, and mixture of 
water and isopropanol at pH 3 (Table 5). The maximum solubility of ITR-HCl found in water 
and isopropanol mixture (50:50 v/v) at pH 3 was 37.52 mg/ml which was ~ 181 folds more when 
compared with ITR (0.207 mg/ml) (Table 5).  
 Solubility of ITR and ITR-HCl (mg/ml) 
 Water Isopropanol Water pH 3 
Water: Isopropanol ratio (pH 3) 
90:10 80:20 70:30 60:40 50:50 
ITR -- 0.288 -- -- -- -- 0.112 0.207 
ITR-HCl 0.01 15.15 0.04 0.06 0.09 0.13 0.41 37.52 
 
Table 4. The solubility of ITR and ITR-HCl (mg/ml) in different solvent systems 
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                Antifungal activity assays of ITR and ITR-HCl were performed on the fungal cultures 
such as T. rubrum, C. albicans, C. krusei, A. fumigatus and C. neoformans. According to the 
results, antifungal activity of ITR and ITR-HCl did not differ significantly (p>0.05) in terms of 
IC50, MIC and MFC levels against all the fungal species tested in this work (Table 6).  
 ITR (µg/ml) ITR-HCl (µg/ml) 
Organisms IC50 MIC MFC IC50 MIC MFC 
T. rubrum 0.063 ± 0.02 0.26 ± 0.08 >20.0 0.06 ± 0.01 0.31 ± 0.05 >20.0 
C. albicans 0.18 ± 0.07 >20.0 >20.0 0.11 ± 0.05 >20.0 >20.0 
C. Krusei 0.23 ± 0.03 0.87 ± 0.001 1.15 ± 0.25 0.27 ± 0.144 0.84 ± 0.005 1.04 ± 0.15 
A. fumigatus 0.50 ± 0.17 1.04 ± 0.35 6.33 ± 1.35 0.29 ± 0.03 1.06 ± 0.25 6.67 ± 1.04 
C. neoformans <0.02 0.027 ± 0.002 0.03 ± 0.001 <0.02 0.02 ± 0.002 0.03 ± 0.001 
 
Table 5. Antifungal activity of ITR and ITR-HCl on different fungal species. The data represent 
mean ± SD of three determinations. (p>0.05) 
In vitro ITR-HCl Transport studies 
Transport studies of ITR-HCl were performed using porcine hoof as well as excised human toe 
model.  The transport studies were performed by passive and iontophoresis modes using two 
different protocols. Continuous protocol involved continuous application of formulation for 24 
hours. However, in case of continuous protocol also, the applied formulation was replaced every 
8 hours for the sake of having sufficient chloride ions in the donor compartment. In non-
continuous or pulsed protocol, the duration of application was at 8 h per day for three days 
(equivalent to 24 hours) across the porcine hoof membrane as well as in human toe model. These 
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protocols were selected to compare the drug delivery efficiency in two different application 
conditions. The continuous protocol represents a condition where the subject would be applied 
with a device for prolonged duration. The pulsed protocol represents wearing the device only for 
a few hours a day for multiple days. In case of in vitro studies using Franz cell, pH 3 solvent 
system was used in the receiver compartment to maintain sink conditions. Previous studies have 
shown that formulation with pH 3 did not affect the constitution or permeability of the nail 
plate.2,8 
            Anodal iontophoresis was performed because of positive charge on the ITR. Platinum 
wire was used as an anodal electrode in the donor compartment because ITR was found to be 
precipitated due to pH change (pH 3 to ~3.8) of drug solution in the donor compartment by 
interaction with Ag electrode. In case of platinum wire, pH of the donor compartment was 
dropped from 3.0 to 2.5 after the application of iontophoresis for 8 h. After every 8 h, drug 
solution in the donor compartment was replaced with fresh drug solution to avoid further drop in 
pH. AgCl electrode was used as cathode electrode in the receiver compartment. The receiver 
compartment pH was increased to 3.4 at the end of 24 hours. Replacement of fresh buffer 
solution after each sampling was found to keep the pH from going above 3.4. 
Passive versus iontophoresis 
In case of continuous protocol, the cumulative amount of ITR in the receiver compartment after 
application of iontophoresis across the hoof membrane was 0.91 ± 0.11 µg/cm² which was ~ 30 
folds (P<0.05) more than passive (0.03 ± 0.01 µg/cm²). The amount of drug retained in the hoof 
membrane by iontophoresis was 4.8 ± 1.2 µg/mg which was ~ 5 folds (P<0.05) more than 
passive (0.95 ± 0.54 µg/mg) (Table 7). 
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Amount of ITR 
Mode of drug 
loading 
In vitro studies 
24 h study 3 days (8 h/day) study 
Receiver 
compartment 
(µg/cm²) 
Hoof 
membrane 
(µg/mg) 
Receiver 
compartment 
(µg/cm²) 
Hoof membrane 
(µg/mg) 
Passive 0.03 ± 0.01 0.95 ± 0.54 0.08 ± 0.01 1.3 ± 0.60 
Iontophoresis 0.91 ± 0.11 4.8 ± 1.2 2.12 ± 0.30 4.95 ± 1.52 
 
Table 6. In case of in vitro transport studies, the amount of ITR was found in the receiver 
compartment (µg/cm²) and hoof membrane (µg/mg) after continuous and pulse applications of 
iontophoresis for 24 h and 3 days (8 h/day). The data represent mean ± SD of six determinations. 
              In case of pulsed protocol, the cumulative amount of drug transported in the receiver 
compartment by iontophoresis was 2.12 ± 0.30 µg/cm² which was ~ 27 folds (P<0.05) more 
when compared to the passive (0.08 ± 0.01 µg/cm²). On the other hand, the amount of drug 
found in the hoof membrane by the application of iontophoresis was 4.95 ± 1.52 µg/mg which 
was ~ 4 folds (P<0.05) more than passive (1.3 ± 0.60 µg/mg) (Table 7). These studies have 
clearly demonstrated the ability of iontophoresis to enhance the delivery of ionic drugs across the 
nail plate. Iontophoresis was also found to enhance the drug holding capacity of the nail plate. 
Amount of ITR 
Mode of drug 
loading 
Ex vivo studies 
24 h study 3 days (8 h/day) study 
Nail bed (µg/mg) Nail plate (µg/mg) Nail bed (µg/mg) Nail plate (µg/mg) 
Passive 0.003 ± 0.09 1.61 ± 0.73 0.11 ± 0.07 1.75 ± 0.98 
Iontophoresis 1.17 ± 0.60 4.64 ± 1.14 2.65 ± 1.09 4.96 ± 1.64 
Table 7. In case of ex vivo transport studies: the amount of drug was found in the nail bed 
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(µg/mg) and nail plate (µg/mg) after continuous and pulse applications of iontophoresis for 24 h 
and 3 days (8 h/day). The data represent mean ± SD of six determinations. 
Continuous versus pulsed protocol 
In both passive as well as iontophoresis modes, the permeation of drug across the hoof 
membrane was significantly higher in case of pulse protocol as compared to continuous protocol. 
In the case of pulse protocol, although the duration of application of formulation is same as 
continuous protocol, there is pause time between the episodes, during which significant amount 
of drug could diffuse into the sub-ungual tissues (receiver compartment in case of Franz cell 
studies). This is likely to render the nail more receptive to drug uptake during the subsequent 
episode of application. However, in case of continuous protocol, the saturation of nail plate is 
likely to hamper the delivery of drug. However, regardless of the protocol, the amount of drug in 
the hoof membrane appears to saturate and did not differ significantly between continuous and 
pulsed protocols. 
Human nail Vs porcine hoof model  
Porcine hoof has been suggested as a good model for human nail plate.
38
 A good correlation 
between the permeability of drugs across the bovine hoof with that across the human nail plate 
has been reported by Mertin and Lippold.
39
 To assess if there exists any correlation between the 
porcine hoof in Franz cell model with excised cadaver toe model, two correlation plots were 
created. The amount of drug permeated across the hoof membrane at a given mode and protocol 
of delivery was matched with the amount of drug permeated across the nail plate into the nail 
bed when same delivery mode and protocol was used. Similarly, the drug loaded in the hoof in 
Franz cell experiments was matched with the levels in the nail plate in toe model.  The drug load 
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in the porcine hoof membrane vs drug loaded in the nail plate showed an excellent correlation 
(R
2
=0.93) (Figure 18). Whereas, the correlation between the amount of drug permeated across 
the hoof membrane into the receiver compartment and the amount of drug found in the nail bed 
was relatively modest (R
2 
=0.56) (Figure 19). The reason for this poor correlation is likely due to 
lack of clearance in the toe model. Although, the few number of data points are available for 
correlation, there appears to be a clear trend of positive correlation which is likely to strengthen 
with the inclusion of additional data in the future. The present studies have demonstrated that the 
excised human toe model could be an acceptable model to investigate the ungual drug delivery, 
despite its limitations.  
 
Figure 13. Correlation between amount of drug retained in the nail plate and amount of drug 
retained in the hoof membrane after transport studies 
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Figure 14. Correlation between amount of drug permeated across the nail plate and amount of 
drug permeated across the hoof membrane. 
4. Conclusion 
In vitro and ex vivo transport studies have demonstrated the feasibility of iontophoresis technique 
to enhance the trans-ungual delivery of ITR. Iontophoresis also enhanced the amount of drug 
loaded in the nail/hoof.  Pulsed application protocol was found to be superior over the continuous 
application protocol in both passive as well as iontophoresis mode of trans-ungual drug delivery.  
This means in clinical practice, dividing the duration of application into multiple episodes would 
be more beneficial to the subject than continuous application of iontophoresis over long time. 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
3
3.5
4
0 0.5 1 1.5 2 2.5
A
m
o
u
n
t 
o
f 
IT
R
 p
er
m
ea
te
d
 
a
cr
o
ss
 t
h
e 
n
a
il
 p
la
te
(µ
g
/c
m
2
)
 
Amount of drug permeated across the hoof membrane 
(µg/cm2) 
34 
 
CHAPTER 4: IONTOPHORESIS FOR DRUG DELIVERY INTO THE NAIL 
APPARATUS: EXPLORING HYPONYCHIUM AS THE SITE OF DELIVERY 
1. Introduction 
The topical delivery of antifungal drugs from dorsal side of the nail plate to deeper layers and 
nail bed is limited and tedious due to poor permeability of the nail plate.
2,3,11
 Therefore, the 
current project was aimed to investigate the feasibility of utilizing the hyponychium pathway to 
deliver antifungal drugs directly into the ventral layer of the nail plate and other parts of the nail 
apparatus.  
     Naturally, nail plate has a structure that allows the distribution of drug molecule from one 
region to other regions of the nail plate by lateral diffusion.
40
 However, passive lateral diffusion 
of drug in  nail plate is very tedious.
40
 Therefore, iontophoresis technique was used as a tool to 
improve the delivery and distribution of the drug into the ventral layer of the nail plate. 
Iontophoresis delivery has already been reported to enhance the delivery of drugs from dorsal to 
ventral layer of the nail plate.
3,8,13,41
 
     In vitro transport studies were performed across the human cadaver nail plates. Sodium 
fluorescein was used as a maker to investigate the feasibility of application of iontophoresis to 
propagate the substrate in the ventral layer of the nail plate. Further, ex vivo investigations were 
performed on excised human cadaver toe using terbinafine hydrochloride, as a leading antifungal 
model drug.  
2. Materials and methods 
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2.1. Materials 
Terbinafine hydrochloride and sodium fluorescein were purchased from Sigma-Aldrich (St. 
Louis, MO). Human nails and excised human cadaver toes were purchased from Science care 
(Phoenix, AZ). Phosphate-buffered saline (PBS) and acetonitrile were purchased from Omnipur 
and Fisher chemicals (Hanover Park, IL). Hydroxypropylmethyl cellulose was received from 
Dow Chemical Company (Midland, MI). 
2.2. In vitro transport studies 
In vitro permeation studies were performed across the human nail plate using Franz diffusion 
apparatus (Logan Instruments LTD, Somerset, NJ) for 24 h. Sodium fluorescein was used as a 
model transporting substance. Before performing an experiment, nail plates were soaked in PBS 
for 2 h. And then they were sandwiched between top and bottom compartments of the Franz 
diffusion cells with their ventral side facing toward the bottom compartment. The top 
compartment was filled with 0.5 ml of PBS and the bottom compartment was filled with 5ml of 
sodium fluorescein solution (1 mg/ml), respectively. Cathodal iontophoresis was performed by 
fixing cathode and anode electrodes in the bottom and top compartments respectively at a 
distance of 2 mm from the nail plate. Silver and silver chloride electrodes were used as anode 
and cathode electrodes and constant direct current (0.5 mA/cm2) was applied across the nail 
plate using iontophoresis device (Active dose II iontophoresis delivery unit, Transport 
Pharmaceuticals, Boston, MA). The bottom compartment solution was stirred continuously 
during the experiment using 3 mm magnetic bars at 600 rpm to distribute the permeated 
fluorescein dye homogenously. PBS in top compartment was replaced with fresh buffer every 
two hours. Passive transport studies were performed simultaneously with a similar set up, along 
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with iontophoresis in which no current was applied. The amount of drug retained in the nail plate 
was quantified by high-performance liquid chromatography (HPLC).
3,13-15
 
2.3. Extraction of sodium fluorescein from the nail plate 
After in vitro transport studies, the nail plates were detached from adaptor using forceps. The 
amount of sodium fluorescein retained in the nail plate was extracted by solvent extraction 
method. The active and lateral diffusion areas of the nail plate were carefully excised using 
metric punch apparatus. Every nail plate was washed out five times by shaking in ethanol and 
water alternatively using forceps and then wiped off completely with Kimwipes®. Each nail 
plate was cut into small pieces and solubilized in 1.5 ml of 1 M sodium hydroxide solution, 
followed by neutralization with 200 ml of 5 M hydrochloric acid.
42-44
 Then, 2 ml of ethyl acetate 
was added and centrifuged the final mixture at 2000 rpm for 10 min for the complete phase 
separation of solvent layers. Finally, ethyl acetate layer was collected and evaporated using 
nitrogen evaporator to get solid crystals of the fluorescein dye.
3,13-15
 Then, sodium fluorescein 
was reconstituted in water and quantified by HPLC.
45
 
2.4. Histological studies of the nail plate 
After transport studies, nail plates were embedded in the paraffin wax and transverse sections of 
the nail plates (10 mm) were prepared using Reichert-Jung 820 histocut microtome equipment 
(GMI, MN). All the images of the transverse sections were taken on 10x magnification using 
Eclipse 90i Microscope (Nikon, NY).
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2.5. Ex vivo transport studies in cadaver toe model 
Ex vivo transport studies was performed on excised human cadaver toe for three days (8 h/day). 
Terbinafine hydrochloride was used as a model drug. HPMC gel (2% w/v hydroxypropyl 
methylcellulose) containing 1% w/v terbinafine hydrochloride was prepared for transport 
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studies.
24,47
 One day before the experiment, cadaver toe was treated with 0.5% w/v gentamycin 
solution and stored at -20 ºC. Before starting the experiment, toe was thawed at room 
temperature. HPMC gel was placed at hyponychium region of the toe and covered by an 
adhesive tape. During the experiment, toe was kept wet using foam sheet. Silver (anode 
electrode) and silver chloride (cathode electrode) electrodes were placed at the hyponychium 
and proximal nail fold regions on the toe (Figure 20). Anodal iontophoresis was performed for 
transport studies. Constant direct current (0.5 mA/cm
2
) was applied using iontophoresis device 
(Active dose II iontophoresis delivery unit, Transport Pharmaceuticals, Boston, MA). Passive 
permeation studies were performed as a control. The formulation was replaced three-four times 
during iontophoresis and in passive by breaking the process for 2–3 min. The amount of drug 
retained in the nail bed, nail plate and nail matrix were extracted and quantified using HPLC 
method.
3,16
 
 
Figure 15. Schematic diagram of ex vivo transport studies of terbinafine hydrochloride from 
hyponychium region 
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2.6. Extraction of drug from nail plate, nail bed and nail matrix 
After transport studies, the nail plate was isolated from the intact toe and washed out five times 
separately by each of alcohol and water. After every washing, each nail plate was wiped 
off with Kimwipes® and then solubilized in the 1.5 ml of 1 M sodium hydroxide solution by 
subjecting under ultra-sonication for 2 h. The alkaline solution was neutralized by adding 200 ml 
of 5 M hydrochloric acid, followed by adding 3 ml of hexane for the extraction of terbinafine.
42-
44
 The mixture was centrifuged at 3000 rpm for 15 min, and then, hexane layer was collected. 
Eventually, 1 ml of 0.5 M sulfuric acid–isopropyl alcohol mixture (85:15) was added to the 
hexane solution and shaken vigorously for 30 min. After shaking, acidic aqueous layer was 
carefully separated from the mixture. And then, the amount of drug extracted from the nail plate 
was quantified using HPLC.
42-44
 
After permeation studies, the amount of terbinafine hydrochloride permeated into the nail bed 
and nail matrix was extracted and quantified following same method discussed earlier.
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2.7. Analytical method 
High performance liquid chromatography system (HPLC) was used to quantify the amount of 
terbinafine in the samples. HPLC system consisted of an autosampler (waters 717 plus), 
Phenomenex C18 (2) 100 R analytical column (4.6 mm × 150 mm, Luna, 5.0 μm), Waters® dual 
wavelength UV detector (2487) was used. Mobile phase was prepared by combination of two 
solvents, aqueous phase (0.096 M triethyl amine, 0.183 M orthophosphoric acid) and acetonitrile 
(60:40). The final pH of the mobile phase was adjusted to pH 2 using orthophosphoric acid. The 
drug was eluted using isocratic solvent system at a flow rate of 1.0 ml/min at the temperature of 
32 ºC. Terbinafine was detected at 224 nm wavelength. To validate the method, calibration curve 
was prepared from the range of 0.1 to 10 μg /ml (R2 = 0.99).8 
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The amount of sodium fluorescein in the samples was quantified using same HPLC set up 
(mentioned above) including fluorescence detector. Mobile phase was prepared by mixing 
acetonitrile, water and triethyl amine (4.0: 5.95: 0.05) at certain ratio. The final pH of the mobile 
phase was adjusted to pH 3 using orthophosphoric acid. Elution of sodium fluorescein was 
carried out isocratically at a flow rate of 1 ml/m. The sodium fluorescein was detected at the 
excitation wavelength of 460 nm and emission wavelength of 515 nm. Retention time of the 
fluorescein was found at ~9.30 min. Calibration curve was prepared from the range of 0.001 to 
10 μg/ml (R2 = 0.99).45 
2.8. Data Analysis 
The statistical analysis of the transport studies was carried out by one-way analysis of variance 
(ANOVA) test and p values less than 0.05 was considered statistically significant. 
3. Results and Discussion 
 
Figure 16. Transverse section of nail plate. [Dorsal layer (DL), Ventral layer (VL)] 
The human nail plate is known to consist of three different layers; dorsal, ventral and 
intermediate. Due to histological similarity between intermediate and ventral layers, only two 
layers of the nail plate are distinctly identified in the optical microscopic picture shown in Figure 
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21.
3,11
 According to Kabayashi, the dorsal layer of the nail plate acts as the predominant barrier 
and limits the transportation of drugs into deeper stratums of the nail apparatus.
11
 Several other 
groups have also confirmed that the drug transport into the nail apparatus increases when the 
dorsal layer of the nail plate is abraded.
37,38,48-51
 Therefore, the present work was aimed to 
investigate the feasibility of utilizing the hyponychium pathway to deliver antifungal drugs 
directly into the ventral layer of the nail plate and other parts of the nail apparatus. The 
hyponychium is an area of the nail bed epithelium that underlies free edge of the nail plate. 
Iontophoresis technique was used as a tool to improve the delivery and distribution of the drug 
into the ventral layer of the nail plate. In vitro and ex vivo transport studies were performed to 
assess the effectiveness of iontophoresis for enhancing the permeation of drug molecule into the 
nail plate and other parts of the nail apparatus. 
3.1. In vitro transport studies 
In case of iontophoresis, the active electrode was placed in the bottom compartment and counter 
electrode was fixed in the top compartment. The amount of sodium fluorescein loaded in the nail 
plate after application of cathodal iontophoresis was 92.4 ± 7.6 ng/ mg which was ~54 fold more 
than passive (1.7 ± 0.7 ng/mg) (Figure 22). The amount of sodium fluorescein retained in the 
peripheral area of the nail plate in the case of iontophoresis (25.5 ± 9.03 ng/mg) was found to be 
~30-folds more compared to passive (0.85 ± 0.2 ng/mg) (Figure 23). In vitro transport studies 
have clearly demonstrated that iontophoresis from ventral side of the nail plate might be a 
potential option for delivery of drugs into the deeper layers of the nail plate. 
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Figure 17. The amount of sodium fluorescein retained in the active diffusion area of the nail 
plate after 24 h in vitro transport studies. The data represent mean ± SD of six determinations. 
 
Figure 18. The amount of sodium fluorescein retained in the peripheral area of the nail plate 
after 24 h in vitro transport studies. The data represent mean ± SD of six determinations. 
3.2. Histological studies 
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As the results of histological studies, the penetration depth of sodium fluorescein in the nail plate 
after application of iontophoresis was found 240 mm of total thickness (254 mm) of the nail 
plate. In case of passive, the penetration depth was found approximately 69 mm of total 
thickness of the nail plate (247 mm). Finally, iontophoresis technique improved 4 times more 
penetration of sodium fluorescein in the nail plate than passive (Figure 24). 
 
Figure 19. Transverse sections of the nail plates after in vitro transport studies of sodium 
fluorescein   
3.3. Ex vivo transport studies 
Ex vivo studies were performed on the excised cadaver toe model to assess the practical 
feasibility of iontophoresis from the distal end of the toe. Although the toe model lacks the 
clearance component, it is anatomically similar to in vivo model and found to be the closest 
model to clinical investigation. Terbinafine hydrochloride HPMC gel was used to perform ex 
vivo studies. Iontophoresis was carried out for three days (8 h/day). The amount of drug retained 
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in the nail plate in the case of iontophoresis was 3.43 ± 1.34 mg/mg, which was 20-fold more 
when compared with passive (0.17 ± 0.10 mg/mg). In case of iontophoresis, the amount of drug 
found in the nail bed and nail matrix were 1.73 ± 0.124 mg/mg and 0.55 ± 0.22 mg/mg (Figure 
25). However, in case of control, there was no detectable amount of terbinafine found in the nail 
bed and nail matrix. 
 
Figure 20. The amount of terbinafine retained in the nail pate, nail bed and nail matrix after ex-
vivo transport studies for 3 days (8 h/ day). The data represent mean ± SD of three 
determinations. 
4. Conclusions 
Iontophoresis from the hyponychium end appears to be a viable option for the delivery of drugs 
into the nail plate and other parts of nail apparatus. However, this approach is limited by small 
area of hyponychium available for the application of formulation. 
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CHAPTER 5: PRE-TREATMENT WITH SOLID MICRONEEDLES FOR UNGUAL 
AND TRANS-UNGUAL DELIVERY OF DRUGS 
1.0 Introduction 
Microneedle pre-treatment is a novel approach which has already been used to deliver small and 
large molecules into the skin in a minimally invasive manner.
17-19,52
 The application of 
microneedles has not been explored before to improve nail delivery of drugs.
18,53
 In this project, 
solid microneedle pre-treatment was investigated to enhance the delivery of drugs into the nail 
apparatus. In vitro permeation studies were performed across the human nail plate pretreated 
with 0.5 mm solid titanium microneedles. Sodium fluorescein was used as a model dye. After 
permeation studies, the amount of sodium fluorescein found into and permeated across nail plate 
was quantified using HPLC method. Microscopic studies were performed to show the 
distribution of sodium fluorescein in nail plate. 
2.0 Materials and Methods: 
2.1 Materials 
Dermal stamp (0.5 mm) was purchased from GHgate. Sodium fluorescein was purchased from 
Sigma-Aldrich (St. Louis, MO). Human nails were procured from Science Care (Phoenix, AZ). 
The solvents were bought from Fisher Chemicals (Hanover Park, IL). 
45 
 
 
Figure 21. Image of titanium microneedles of dermal stamp  
2.2 In vitro permeation studies: 
In vitro transport studies were performed across the human nail plate using Franz diffusion 
apparatus (Logan Instruments Ltd, Somerset NJ) for 7 days. Sodium fluorescein was used as a 
model dye for transport studies. Before performing an experiment, nail plates were hydrated in 
phosphate buffer saline (PBS) for 2 h. Nail plate was pretreated with 0.5 mm long titanium 
microneedles and then sandwiched between donor and receiver compartments using nail adapter 
(PermeGear, Hellertown, PA) having 0.3 cm
2 
active diffusion area. Nail plate with no 
microneedles pretreatment was used as a control. Donor compartment was filled with 0.5 ml of 1 
mg/ml sodium fluorescein solution in PBS. Receiver compartment was filled with 5ml of 
phosphate buffer saline. The solution in receiver compartment was stirred continuously during 
the experiment using 3 mm magnetic bars at 600 rpm to distribute the permeated fluorescein dye 
homogenously. Samples were collected at definite period of time from receiver compartment. 
The amount of sodium fluorescein contained in samples was quantified using HPLC method.
3,13-
15
 
2.3 Extraction of sodium fluorescein from the nail plate 
After in vitro transport studies, nail plates were separated from an adaptor using forceps. Active 
diffusion area of nail plate was excised using 0.3 cm
2
 metric dermal punch. Then, nail plates 
were washed 5 times with 50% of ethanol and wiped off with Kimwipes
® 
to remove the extra 
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amount of sodium fluorescein presented on its outer surface. The amount of sodium fluorescein 
retained in nail plate was extracted using solvent extraction method. Each nail plate was weighed 
accurately before solubilizing in 1.5 ml of 1 M sodium hydroxide solution. Hydrochloric acid (5 
M, 200 µl) was added to neutralize alkaline solution. Finally, ethyl acetate (2 ml) was added as 
an extraction solvent and the mixture was centrifuged at 2000 rpm for 10 min. After complete 
phase separation of solvent layers, ethyl acetate layer was collected and evaporated using 
nitrogen evaporator to get solid crystals of fluorescein dye.
3, 13 
The amount of sodium fluorescein 
was quantified by HPLC.
45
 
The amount of drug diffused in peripheral area of nail plate was extracted and quantified 
following same method which was mention above in same section 2.3.
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2.4. Microscopic studies of solid microneedles pretreated nail plates: 
Microscopic studies were performed to show the distribution of sodium fluorescein in nail plate. 
In this case, in vitro permeation studies were performed for 24 h and then active diffusion area of 
nail plate was excised using dermal metric punch. All nail plates were washed with 90% alcohol 
and wiped off with Kimwipes
® 
to remove the extra amount of sodium fluorescein presented on 
its surface. Finally, nail plate was embedded in the paraffin wax. Reichert-Jung 820 histocut 
microtome equipment (GMI, MN, USA) was used to prepare transverse and horizontal sections 
(10 µm) of nail plates. All the images of transverse and horizontal sections were taken using 
Eclipse 90i Microscope (Nikon, NY, USA) at 10X magnification.
45
 
2.5. Analytical method: 
High performance liquid chromatography system (HPLC) was used to quantify the amount of 
sodium fluorescein presented in the samples. HPLC system consists of an autosampler (waters 
717 plus), Phenomenex C18 (2) 100 R analytical column (4.6 mm × 150 mm, Luna, 5.0 µm), 
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fluorescence detector. Mobile phase was prepared by mixing acetonitrile, water and triethyl 
amine (4.0: 5.95: 0.05) at certain ratio. The final pH of the mobile phase was adjusted to pH 3 
using orthophosphoric acid. Elution of sodium fluorescein was carried out isocratically at a flow 
rate of 1 ml/min. The sodium fluorescein was detected at the excitation wavelength of 460 nm 
and emission wavelength of 515 nm. Calibration curve was prepared from the range of 0.001 to 
10 µg/ml (R
2 
= 0.99).
45
 
3.0 Results and discussion 
Ungual and trans-ungual delivery of drugs is restricted due to tough nature of dorsal layer of the 
nail plate.3,8-10 In previous literatures, several passive and active techniques have been reported to 
disruption the dorsal layer of nail plate to improve the transportation of drugs.
12
 Although, solid 
microneedles are widely used for the delivery of small and larger molecules into the skin, its 
application for nail delivery of drugs have not been investigated yet. Therefore, in this project, 
the application of microneedles was investigated to improve the permeation of drugs into and 
across nail plate. Different length of solid microneedles (0.2 mm, 0.3 mm, 0.5 mm) were tried to 
create holes deeper enough to ventral layer of nail plate. After all the observations, 0.5 mm 
microneedles were found to be more efficient to perform further studies.  
In vitro permeation studies:   
As a result of in vitro permeation studies, the amount of sodium fluorescein found in receiver 
compartment was 86.2±13.4 ng/cm² which was ~123 fold more compared to control (0.7±0.28 
ng/cm²). The amount of sodium fluorescein retained in nail plate in case of microneedles 
(0.4±0.01 µg/mg) was found to be ~4 fold more related to control (0.10±0.01 µg/mg).  The 
amount of sodium fluorescein diffused in the peripheral area of nail plate was 1.17±0.07 µg/mg 
which was found to be ~3 fold more compared to control (0.371.6±0.04 µg/mg).  
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Figure 22. The amount of sodium fluorescein permeated across the nail plate after 7 days of in 
vitro transport studies (µg/cm
2
). The data represent mean ± SD of six determinations.  
 
Figure 23. The amount of sodium fluorescein retained in the nail plate after 7 days of in vitro 
transport studies. The data represent mean ± SD of six determinations. 
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Figure 24. The amount of sodium fluorescein found in peripheral area of nail plate after 7 days 
of in vitro transport studies. The data represent mean ± SD of six determinations.  
3.2 Microscopic studies: 
Titanium microneedles created approximately 62 pixels (~16 µm) average diameter of holes in 
nail plate. After 24 h of in vitro studies, nail plates were cut in approximately 10 µm thickness of 
transverse and horizontal sections. The distribution of sodium fluorescein was imaged at 10x 
magnification using Eclipse 90i Microscope. In case of microneedles pre-treatment, images 
showed the distribution of sodium fluorescein in all three layers of the nail plate. However, 
fluorescein dye was observed only on top layer of nail plate in case of control. 
 
0.0
0.1
0.2
0.3
0.4
0.5
Control Microneedles
T
h
e 
a
m
o
u
n
t 
o
f 
d
ru
g
 d
if
fu
se
d
 
p
er
ip
h
er
a
ll
y
 i
n
 t
h
e 
n
a
il
 p
la
te
 (
µ
g
/m
g
) 
50 
 
 
 
Figure 25. Horizontal sections of nail plate after treatment with solid titanium microneedles. The 
image was taken from dorsal layer of nail plate.  
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Figure 26. Transverse sections of nail plates after 24 h of in vitro transport studies of sodium 
fluorescein. 
4.0 Conclusion: Pre-treatment of nail plate with solid microneedles was able to deliver 
significant amount of sodium fluorescein into and across the nail plate. It is evident that pre-
treatment with microneedles could be a potential option for ungual and trans-ungual delivery of 
drugs for the treatment of nail diseases.   
 
Transverse sections of microneedles pre-treated nail plate 
Transverse sections of nail plate (Control) 
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 Accomplished PhD in Pharmaceutics with research expertise in novel pharmaceutical 
pre-formulation and formulation development, design, testing and analysis with special 
focus on transdermal, topical and transungual (Nail) drug delivery systems.  
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 Developed a novel epidermis preparation method which is a critical step in performing 
transdermal and topical permeation studies.   
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Microneedles). 
 Conducted pharmacokinetic studies in plasma, skin and brain utilizing intravenous and 
transdermal application methods in rat models.   
 Overseen all laboratory activities and supervised lab personnel. 
 
Laboratory & Technical Experience  
 Development of pre-formulation and formulation of topical, transdermal and trans-ungual 
dosage forms utilizing: 
o In vitro drug permeation studies across skin, nail and nasal tissues using vertical 
& horizontal diffusion apparatus.  
o Passive (chemical penetration enhancers) and physical drug delivery techniques 
(Iontophoresis, Ultrasonic, Microneedles and Electrophoresis) 
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